At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to ...

Pfizer Inc. (NYSE:PFE – Get Free Report) traded up 0.4% during trading on Wednesday . The stock traded as high as $26.65 and ...

Also Read: Pfizer's Paxlovid Demonstrates Safety But ... that traditional medical records may overlook. Extended antiviral courses have precedent in other conditions like HIV and hepatitis C ...